Mirae Asset Global Investments Co. Ltd. Reduces Stock Holdings in Humana Inc. (NYSE:HUM)

Mirae Asset Global Investments Co. Ltd. decreased its holdings in Humana Inc. (NYSE:HUM) by 11.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,560 shares of the insurance provider’s stock after selling 2,007 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Humana were worth $4,117,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in Humana by 7.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider’s stock worth $244,811,000 after acquiring an additional 65,735 shares during the period. denkapparat Operations GmbH purchased a new stake in Humana in the fourth quarter worth $323,000. Allstate Corp purchased a new stake in Humana in the fourth quarter worth $905,000. Deutsche Bank AG lifted its stake in Humana by 18.2% in the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider’s stock worth $160,185,000 after acquiring an additional 97,071 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new stake in Humana in the first quarter worth $1,309,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUM. Raymond James Financial raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a research note on Thursday, May 1st. Robert W. Baird increased their price objective on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, April 15th. Bank of America decreased their price objective on Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a report on Tuesday, June 17th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Finally, Wall Street Zen upgraded Humana from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $280.76.

Humana Price Performance

Shares of NYSE:HUM opened at $252.38 on Wednesday. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The business has a fifty day moving average price of $241.77 and a 200-day moving average price of $258.95. The company has a market capitalization of $30.46 billion, a PE ratio of 17.85, a PEG ratio of 1.84 and a beta of 0.44.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. During the same period last year, the company earned $7.23 EPS. Humana’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, equities analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.40%. Humana’s payout ratio is 25.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.